Edarbi (azilsartan medoxomil tablets; Takeda) is available for the treatment of hypertension in adults. Additionally, Takeda announced that the FDA has approved updated product labeling for Edarbi, which highlights the connection between lowering blood pressure and decreased risks of cardiovascular outcomes, including strokes and heart attacks. The new product label reflects FDA guidance released in March 2011 for manufacturers of all antihypertensive treatments. The guidance stated, “blood pressure control is well established as beneficial in preventing serious cardiovascular events, and inadequate treatment of hypertension is acknowledged as a significant public health problem.”

Edarbi is available in 40mg and 80mg dosage strengths.

For more information call (877) 825-3327 or visit www.edarbi.com.